GALECTIN-3 nsSNP MARKER FOR CANCER
A diagnostic biomarker including a mechanism for determining a patient's propensity to develop cancer. A diagnostic kit for determining a patient's propensity to develop cancer. A method of predicting both a patient's and a population's propensity to develop cancer, by detecting the presence of an H 64 and/or P 98 allele of galectin-3 from a patient's serum sample, and predicting that the patient or population has the propensity to develop cancer based on the presence of the allele. A method of providing prophylactic cancer treatment, by detecting the presence of an H 64 and/or P 98 allele of galectin-3 from a patient's serum sample, predicting that the patient has the propensity to develop cancer based on the presence of the allele, and recommending and providing prophylactic treatment to the patient to reduce their risk of cancer. A prophylactic anticancer treatment and method of preventing onset or further proliferation of cancer.
1 . A method of predicting propensity to develop cancer, including the steps of:
detecting the presence of an allele of galectin-3 chosen from the group consisting of a homozygous H64 allele, a heterozygous H64 allele, a homozygous P98 allele, a heterozygous P98 allele, and combinations thereof from a patient's serum sample; and
predicting that the patient has the propensity to develop cancer based on the presence of the allele.
2 . The method of claim 1 , wherein the cancer is breast cancer.
3 . The method of claim 1 , wherein the detecting step is further defined as detecting the allele by analyzing a component of the patient's serum chosen from the group consisting of DNA, mRNA, and protein.
4 . A method of predicting a population's propensity to develop cancer, including the steps of:
detecting the presence of an allele of galectin-3 chosen from the group consisting of a homozygous H64 allele, a heterozygous H64 allele, a homozygous P98 allele, a heterozygous P98 allele, and combinations thereof from serum samples of patients in a population; and
predicting the percentage of the population that has the propensity to develop cancer based on the presence of the allele.
5 . The method of claim 4 , wherein the cancer is breast cancer.
6 . The method of claim 4 , wherein the detecting step is further defined as detecting the allele by analyzing a component of the patient's serum chosen from the group consisting of DNA, mRNA, and protein.
7 . A method of providing prophylactic cancer treatment, including the steps of:
detecting the presence of an allele of galectin-3 chosen from the group consisting of a homozygous H64 allele, a heterozygous H64 allele, a homozygous P98 allele, a heterozygous P98 allele, and combinations thereof from a patient's serum sample;
predicting that the patient has the propensity to develop cancer based on the presence of the allele; and
recommending and providing prophylactic treatment to the patient to reduce their risk of cancer.
8 . The method of claim 7 , wherein said prophylactic treatment is chosen from the group consisting of preventative surgery, preventative drug treatment, and combinations thereof.
9 . The method of claim 7 , wherein the cancer is breast cancer. The method of claim 7 , wherein the detecting step is further defined as detecting the allele by analyzing a component of the patient's serum chosen from the group consisting of DNA, mRNA, and protein.